Viridian Therapeutics to Participate in Upcoming May Investor Conferences

Rhea-AI Summary

Viridian Therapeutics, a biopharmaceutical company (NASDAQ: VRDN), will participate in investor conferences in May 2024. The company aims to present potential best-in-class medicines for serious and rare diseases at the RBCCM Global Healthcare Conference in New York and the BofA Securities Health Care Conference in Las Vegas.

WALTHAM, Mass.--(BUSINESS WIRE)-- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in the following upcoming investor conferences in May:

• 2024 RBCCM Global Healthcare Conference (New York, NY): Presentation on Tuesday, May 14, 2024, at 8:30 a.m. ET.

• BofA Securities 2024 Health Care Conference (Las Vegas, NV): Presentation on Wednesday, May 15, 2024, at 4:35 p.m. PT.

A live webcast of each presentation can be accessed under “Events and Presentations” on the Investors section of the Viridian website at viridiantherapeutics.com. A replay of the webcasts will be available following the completion of the event.

About Viridian Therapeutics

Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.

Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting a pivotal program for VRDN-001, including two global phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate its efficacy and safety in patients with active and chronic TED. Viridian’s goal is to advance VRDN-001 as a potential best-in-class intravenous therapy followed by VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED.

In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

Viridian is based in Waltham, Massachusetts. For more information, please visit www.viridiantherapeutics.com. Follow Viridian on LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240510199739/en/

Louisa Stone, 617-272-4604

Manager, Investor Relations

IR@viridiantherapeutics.com

Source: Viridian Therapeutics, Inc.

FAQ

When will Viridian Therapeutics participate in investor conferences in May 2024?

Viridian Therapeutics will participate in the RBCCM Global Healthcare Conference on May 14, 2024, and the BofA Securities Health Care Conference on May 15, 2024.

Where will the RBCCM Global Healthcare Conference take place?

The RBCCM Global Healthcare Conference will take place in New York, NY.

Where can investors access the live webcast of the presentations?

Investors can access the live webcast of the presentations under 'Events and Presentations' on the Investors section of the Viridian website at viridiantherapeutics.com.